U.S. health regulators authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand for vaccines and boosters is low, the Wall Street Journal reported. The Food and Drug Administration said adults 18 and older may receive Novavax’s vaccine, once the shots have been approved by the CDC, expected in the coming days. The news comes as the daily average for new cases is ticking higher and stood at 130,511 on Wednesday, according to a New York Times tracker, up 16% from two weeks ago. The daily average for hospitalizations…
This article was originally published by Marketwatch.com. Read the original article here.
